Differential Inactivation of CDKN2 and Rb Protein in Non—Small-Cell and Small-Cell Lung Cancer Cell Lines (original) (raw)

Journal Article

,

NCI Navy Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute

Bethesda, Md

Correspondence to : Michael J. Kelley, M.D., NCI-Navy Medical Oncology Branch, Bldg. 8, Rm. 5105, National Naval Medical Center, Bethesda, MD 20889–5105.

Search for other works by this author on:

,

NCI Navy Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute

Bethesda, Md

Search for other works by this author on:

,

Biostatistics and Data Management Section, Division of Cancer Treatment, National Cancer Institute

Bethesda, Md

Search for other works by this author on:

,

NCI Navy Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute

Bethesda, Md

Search for other works by this author on:

,

Myriad Genetics, Inc.

Salt Lake City, Utah.

Search for other works by this author on:

NCI Navy Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute

Bethesda, Md

Search for other works by this author on:

Received:

02 September 1994

Revision received:

19 January 1995

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Michael J. Kelley, Kazuhiko Nakagawa, Seth M. Steinberg, James L. Mulshine, Alexander Kamb, Bruce E. Johnson, Differential Inactivation of CDKN2 and Rb Protein in Non—Small-Cell and Small-Cell Lung Cancer Cell Lines, JNCI: Journal of the National Cancer Institute, Volume 87, Issue 10, 17 May 1995, Pages 756–761, https://doi.org/10.1093/jnci/87.10.756
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Background : The CDKN2 gene encodes the human cyclin-dependent kinase 4 inhibitor. This inhibitor protein is believed to be a tumor suppressor that plays an essential role in cell cycle regulation. One half of all cancer cell lines and one fourth of lung cancer cell lines examined to date contain homozygous deletions (i.e., both alleles lost) of CDKN2. However, the relative frequency of homozygous CDKN2 deletions in non-small-cell lung cancers (NSCLC) and in small-cell lung cancers (SCLC) has not been determined. Inactivation or loss of another tumor suppressor encoded by the retinoblastoma gene (the Rb protein) is more common in SCLC than in NSCLC. Purpose : We measured the frequency of homozygous CDKN2 deletions in 77 NSCLC and in 93 SCLC tumor cell lines. In addition, possible associations were explored between CDKN2 gene loss, the presence or absence of Rb protein, and the clinical status of lung cancer patients. Methods : DNA was isolated from each tumor cell line and from the primary tumor and normal tissue of one NSCLC patient. Sequences corresponding to exons 1 and 2 of the CDKN2 gene were amplified by use of the polymerase chain reaction, and the resulting amplification products were analyzed by agarose gel electrophoresis and DNA blotting. Genomic DNA blotting was also used to evaluate CDKN2 gene deletions. The frequency of homozygous CDKN2 loss and the presence or absence of functional Rb protein (reported previously) in the cell lines were compared. Results : Homozygous deletion of CDKN2 was detected in 18 (23%) of 77 cell lines established from patients with NSCLC, compared with one (1%) of 93 cell lines established from patients with SCLC (P<.001). No CDKN2 gene loss was observed in the normal tissue of an NSCLC patient whose tumor cell line showed homozygous deletion of the gene; however, the primary tumor from this patient had evidence of CDKN2 loss. Homozygous CDKN2 deletion was detected in 13 (28%) of 46 tumor cell lines from patients with stage III or stage IV NSCLC, compared with zero of 10 tumor cell lines from patients with stage I or stage II NSCLC. Coincident loss of CDKN2 genes and functional Rb protein was rarely observed (in two of 135 cell lines). Conclusion: The frequency of homozygous CDKN2 gene deletion in NSCLC cell lines is greater than that observed for any other known, or candidate, tumor suppressor gene. Implication : Further study of the role of CDKN2 gene alteration in the pathogenesis of NSCLC is needed. [J Natl Cancer Inst 87: 756–761, 1995]

This content is only available as a PDF.

© Oxford University Press

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Differential Inactivation of CDKN2 and Rb Protein in Non—Small-Cell and Small-Cell Lung Cancer Cell Lines - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 45

10 Pageviews

35 PDF Downloads

Since 12/1/2016

Citations

89 Web of Science

×

Email alerts

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic